TheTechno Optimist.

ElecoglipronAstraZeneca—AstraZeneca SOLSTICE Phase 2b trial shows elecoglipron reduced HbA1c by 1.9% in type 2 diabetes at 26 weeksElecoglipronAstraZeneca—AstraZeneca presents Phase 2b VISTA data for elecoglipron: 11.8% weight loss at 36 weeks in obesityESO-T01AstraZeneca—ESO-T01 Phase 1 for multiple myeloma published in Nature Medicine; all patients developed Grade 3+ cytokine release syndrome

ESO-T01

by AstraZenecaGB

An in vivo CAR-T therapy for relapsed/refractory multiple myeloma. Uses a lentiviral vector carrying an anti-BCMA CAR gene infused as a single IV dose without leukapheresis or ex vivo manufacturing.

PilotStage 3 of 5

Phase 1 showed efficacy but all patients developed severe cytokine release syndrome. Development ongoing.

Updated Apr 2026Checked 10 Oct0 updates this week

Milestones

No announced next step
  1. EsoBiotec acquisition completed by AstraZeneca20 May 2025Complete.
  2. Phase 1 trial dosing and evaluation2025Complete.
  3. Phase 1 results published in Nature MedicineApr 2026Complete.

Most important updates

Primer